$MENS News

Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025

Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio

Jyong Biotech Advances Market Access Strategies For Its Plant-Based Drugs Botreso And PCP After Analysis Of Their Clinical Efficacy And Competitive Advantages

Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2

Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia

Jyong Biotech Completes Phase II Trial For MCS-8, Expands Commercial Presence In Asia

CEO Fu-Feng Kuo, Jyong Biotech Ltd.'s (NASDAQ:MENS) largest shareholder sees value of holdings go down 23% after recent drop

Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value

Jyong Biotech Announces Updated Statistical Analyses For Key Blood Biochemical Markers From Phase II Clinical Trial Of MCS-8 Conducted In Taiwan

Jyong Biotech Shares Halted On Circuit Breaker To The Upside, Stock Now Up 66.30%

Jyong Biotech Shares Halted On Circuit Breaker To The Upside, Stock Now Up 42.20%

Jyong Biotech Responds to Share Price and Volume Movement

Jyong Biotech Reaffirms Compliance With Disclosure Obligations Under SEC Regulations, In Discussions With Certain Investment Funds For Share Sale

Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS‑2 Market Entry

Jyong Biotech Enters Into Non-Binding MOU With Vietnam‑Based Pharmaceutical Distribution Company To Evaluate Development And Commercialization Of MCS‑2 In Vietnam

Jyong Biotech: Speculative BPH And Prostate Cancer Prevention Story

Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs

Jyong Biotech Signs MoU With South Korean Pharmaceutical Company To Review, Evaluate Licensing, Development Of Jyong Biotech's Plant-Derived New Drug MCS-2

Jyong Biotech completes primary endpoint analysis for Phase II trial of MCS-8

Exploring Jyong Biotech’s (NasdaqGM:MENS) Valuation Following Recent Share Price Volatility